Top-Line Data on Bexmarilimab Dose Variation
Faron Pharmaceuticals Ltd (“Faron or Company”) Faron Pharmaceuticals Announces Top-Line Data on Bexmarilimab Dose Variation from MATINS Advanced Solid Tumor Patients · Bexmarilimab was well tolerated in patients receiving higher dose levels or frequency of administration · Treatment induced significant systemic interferon (IFN) gamma increase - again showing the capacity of bexmarilimab to activate immune response in cancer patients, especially in patients with immunologically “cold” tumors · Higher baseline Clever-1 levels in the tumors was associated with